SuperNK is a patented immunotherapy
With a culturing technology that mass produces 99% pure NK cells
with superior killing ability.
(PCT patents registered/pending in the U.S., China, Korea, and more.)
Existing NK cell culture technologies mainly use highly concentrated cytokines, which only increase the number of NK cells (proliferation). SuperNK’s novel cell culture technology uses cytotoxicity enhancing agents and proliferating agents that the result is both highly cytotoxic and a large number of NK cells.
SuperNK® has unique patented NK cell culture technology.
Existing NK cell culture technology
Novel NK cell culture technology
Comparison of NK cells’ purity and killing ability between SuperNK vs. others
|Limitation of existing NK cell therapies||Superiority of SuperNK®|
|Generally display decreased killing ability||
|Lower NK cell purity containing a large portion of other immune cells||
|Difficult in vitro mass production||
|Ineffective treatment due to inhibition of Immune function in cancer patients||